Bartter syndrome: genes and variants
Explore variant evidence for Bartter syndrome across 4 analyzed proteins (CLCNKB, SLC12A1, MAGED2, SLC12A3). Linked ClinVar records include 30 pathogenic or likely pathogenic variants, 225 variants of uncertain significance and 29 with conflicting classifications.
Coverage includes proteins already analyzed in CATVariant, not every gene involved in this condition. Database links are associations, not an assessment of clinical gene–disease validity. Computable evidence prioritizes variants for expert review and does not reclassify them. Source labels are pooled across this disease family.
Data updated 2026-11-05. Automated aggregation, not a clinical review date.
Download variant evidence (CSV)
Genes linked to Bartter syndrome
CLCNKB: Chloride channel protein ClC-Kb
It supports chloride reabsorption in the thick ascending limb and distal nephron, helping establish salt balance and the kidney's concentrating gradient. Biallelic loss-of-function variants cause Bartter syndrome type 3 and can sometimes mimic Gitelman syndrome.
16 ClinVar pathogenic / likely pathogenic and 87 uncertain variants in CLCNKB have source records linked to Bartter syndrome. Association strength is not clinical gene validity.
SLC12A1: Solute carrier family 12 member 1
It reabsorbs sodium, potassium, and chloride in the thick ascending limb of the kidney, helping generate the medullary concentration gradient and maintain salt balance. Biallelic loss-of-function variants cause Bartter syndrome type 1 with renal salt wasting.
14 ClinVar pathogenic / likely pathogenic and 160 uncertain variants in SLC12A1 have source records linked to Bartter syndrome. Association strength is not clinical gene validity.
MAGED2: Melanoma-associated antigen D2
It regulates membrane-protein trafficking in renal tubule cells and helps maintain expression of salt-transport proteins during fetal kidney development. Hemizygous loss-of-function variants cause transient antenatal Bartter syndrome, which often improves substantially after birth.
0 ClinVar pathogenic / likely pathogenic and 3 uncertain variants in MAGED2 have source records linked to Bartter syndrome. Association strength is not clinical gene validity.
SLC12A3: Solute carrier family 12 member 3
It reabsorbs sodium and chloride in the distal convoluted tubule and is a major determinant of renal salt and magnesium handling. Biallelic loss-of-function variants cause Gitelman syndrome with hypokalemic metabolic alkalosis, hypomagnesemia, and low urinary calcium.
0 ClinVar pathogenic / likely pathogenic and 3 uncertain variants in SLC12A3 have source records linked to Bartter syndrome. Association strength is not clinical gene validity.
Weakly linked (only a few uncertain records): CASR.
Where Bartter syndrome variants cluster
- CLCNKB Transmembrane (positions 421–440): 6 of 16 ClinVar pathogenic / likely pathogenic variants, 12.9× more than its size predicts (a length-based count, not a validated hotspot).
- SLC12A1 Extracellular (positions 439–550): 6 of 14 ClinVar pathogenic / likely pathogenic variants, 4.2× more than its size predicts (a length-based count, not a validated hotspot).
- SLC12A1 Transmembrane (positions 551–571): 3 of 14 ClinVar pathogenic / likely pathogenic variants, 11.2× more than its size predicts (a length-based count, not a validated hotspot).
ClinVar pathogenic and likely pathogenic variants linked to Bartter syndrome
| Variant | Position | Protein part | Clinical label |
|---|---|---|---|
| CLCNKB R438H | 438 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CLCNKB R438C | 438 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CLCNKB E442G | 442 | Pathogenic / likely pathogenic (★★) | |
| SLC12A1 E368G | 368 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC12A1 A555T | 555 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CLCNKB G424R | 424 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CLCNKB G437R | 437 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CLCNKB L439P | 439 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC12A1 G257S | 257 | Cytoplasmic | Pathogenic / likely pathogenic (★★) |
| SLC12A1 R439Q | 439 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC12A1 G478R | 478 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC12A1 A498V | 498 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC12A1 A508T | 508 | Extracellular | Pathogenic / likely pathogenic (★★) |
| CLCNKB P124L | 124 | Helical | Pathogenic / likely pathogenic (★★) |
| CLCNKB V170M | 170 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| SLC12A1 C475Y | 475 | Extracellular | Pathogenic / likely pathogenic (★★) |
| SLC12A1 G612R | 612 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CLCNKB R92W | 92 | Transmembrane | Pathogenic / likely pathogenic (★★) |
| CLCNKB A204T | 204 | Helical | Pathogenic / likely pathogenic (★★) |
| CLCNKB R351W | 351 | Helical | Pathogenic / likely pathogenic (★★) |
| CLCNKB E442K | 442 | Pathogenic / likely pathogenic (★) | |
| SLC12A1 A510D | 510 | Extracellular | Pathogenic / likely pathogenic (★) |
| SLC12A1 L560P | 560 | Transmembrane | Pathogenic / likely pathogenic (★) |
| SLC12A1 A562V | 562 | Transmembrane | Pathogenic / likely pathogenic (★) |
| CLCNKB A467V | 467 | Helical | Pathogenic / likely pathogenic (★) |
| CLCNKB G470R | 470 | Helical | Pathogenic / likely pathogenic (★) |
| SLC12A1 V272F | 272 | Transmembrane | Pathogenic / likely pathogenic |
| CLCNKB A349D | 349 | Helical | Pathogenic / likely pathogenic |
| SLC12A1 E281D | 281 | Extracellular | Pathogenic / likely pathogenic |
| CLCNKB Y432H | 432 | Transmembrane | Pathogenic / likely pathogenic |
Uncertain variants prioritized for review in Bartter syndrome
| Variant | Position | Protein part | Clinical label | Evidence |
|---|---|---|---|---|
| CLCNKB G470W | 470 | Helical | Uncertain (★) | +6: 2 other pathogenic changes within 3 positions; G470R at the same position is pathogenic; REVEL 0.981 |
Which prediction tools work for Bartter syndrome
Observed separation of ClinVar pathogenic / likely pathogenic from benign / likely benign variants (AUROC × 100). This benchmark is not a clinical recommendation.
- MetaLR: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MetaSVM: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- REVEL: 100 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- CATVariant: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- MutPred: 99 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- EVE: 99 out of 100
- AlphaMissense: 99 out of 100
- SIFT: 98 out of 100
- VARITY: 98 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- ESM1b (LLR): 98 out of 100
- CADD: 97 out of 100
- PolyPhen-2: 96 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- phyloP: 83 out of 100
- phastCons: 76 out of 100
- SpliceAI: 65 out of 100 (learned from overlapping clinical labels, so this is optimistic)
- Pangolin: 28 out of 100 (learned from overlapping clinical labels, so this is optimistic)
Diseases related to Bartter syndrome
- Nephrotic syndrome, also linked to SLC12A1 and SLC12A3
- Familial hypokalemia-hypomagnesemia, also linked to SLC12A3
- Renal tubulopathies, also linked to SLC12A3
- Myocardial infarction, also linked to SLC12A3
- Kidney disorder, also linked to SLC12A1
Frequently asked questions
Which genes have records linked to Bartter syndrome?
This view contains 4 analyzed proteins: CLCNKB, SLC12A1, MAGED2, SLC12A3. Links come from clinical records and association databases. They do not imply that every listed gene is a validated cause, and missing genes may not yet be analyzed.
What do the clinical classifications mean?
Linked records include 30 pathogenic or likely pathogenic variants, 225 variants of uncertain significance and 29 with conflicting classifications. Labels summarize source records; multi-condition records may not make a separate assertion for this disease. Check the original record and review status.
Does the evidence score change a VUS classification?
No. 1 VUS or conflicting variants reach the likely-pathogenic points range on the computable criteria available here. This is a research prioritization signal, not a clinical classification. Patient, family and other required evidence may be missing.
Can I download the variant evidence?
Download the CSV for all 340 variants in the selected disease scope, including clinical labels, review status, evidence criteria, predictor scores, functional measurements and population frequency where available.
About this data
Variant–disease links come from ClinVar, Open Targets and UniProt, pooled from eligible public CATVariant analyses of each human protein. Evidence scores use the ACMG/AMP Bayesian points scale with computable criteria only (position among known disease variants, rarity in gnomAD, calibrated predictors, deep mutational scanning); there is no family or patient data, so they prioritise variants for expert review and never classify them.
Download every variant as CSV · Browse all diseases · Methods · About the Center